4.5 Article

NGS-based IgH gene rearrangement monitoring predicts relapse and guides maintenance therapy in DLBCL: A case report from indolent lymphoma to aggressive lymphoma

Journal

PATHOLOGY RESEARCH AND PRACTICE
Volume 248, Issue -, Pages -

Publisher

ELSEVIER GMBH
DOI: 10.1016/j.prp.2023.154644

Keywords

Mucosa-associated lymphoid tissue (MALT) lymphoma; Diffuse large B cell lymphoma; IgH gene rearrangement; Mutation; Autologous stem cell transplantation

Categories

Ask authors/readers for more resources

This report presents a case study of a 39-year-old female patient with Hashimoto's thyroiditis (HT) who experienced transformation of extranodal marginal zone B-cell lymphoma (ENMZL) of the mucosa-associated lymphoid tissue (MALT) lymphoma to diffuse large B-cell lymphoma (DLBCL). The patient had MALT lymphoma in the thyroid tissue and DLBCL in multiple sites including the ovary, breast, and lymph nodes. Analysis of Ig gene rearrangement and mutation profile showed that the tumor clonotype in the thyroid, ovary, and breast tissues had a shared origin.
This report describes a case of extranodal marginal zone B-cell lymphoma (ENMZL) of the mucosa-associated lymphoid tissue (MALT) lymphoma that transformed to diffuse large B cell lymphoma (DLBCL) in a 39-year-old female patient with Hashimoto's thyroiditis (HT). The patient presented with MALT lymphoma in the thy-roid tissue and DLBCL in the multiple site invasions, including the ovary, breast, and lymph nodes. We assessed the Ig gene rearrangement and mutation profile in lymphoma involved tissues and the collected stem cells. V(D)J sequence of the tumor clonotype detected in thyroid, ovary, and breast was identical, revealing a shared origin of the malignant lymphoma. Noticeably, a small percentage of tumor clonotype (the highest-ranking clonotype in tumor tissues) was detected in the stem cell sample, suggesting the malignant cells was residual in the stem cells, likely conferred disease relapse following ASCT. This patient recieved BTK inhibitor combined with radiotherapy to eradicate the residual tumor cells based on the V(D)J sequence monitoring after ASCT. Now the patient re-mains in complete remission following 12 months of ASCT.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available